Compare MasTec Inc (MTZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Novo Nordisk A/S — how do they compare? MasTec Inc trades at $240.68 (market cap $19.77B), while Novo Nordisk A/S trades at $44.69 (market cap $200.69B). The key difference: Novo Nordisk A/S is far larger — about 10.2× MasTec Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | NVO | |
|---|---|---|
Market Cap | $19.77B | $200.69B |
Sector | Technology | Health |
52-Week High | $437.51 | $63.98 |
52-Week Low | $189.18 | $35.29 |
Enterprise Value | $22.69B | $215.49B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $246.18, up 3.79% today, with strong analyst support (88.9% buy ratings) and a consensus price target of $436.50. The stock shows bearish technical signals but benefits from record $21.4B backlog and AI infrastructure exposure. Recent Q2 2026 earnings missed expectations slightly, though revenue grew 23% year-over-year. The company raised its 2026 outlook, highlighting expanding data center capabilities and power delivery growth.
MTZ presents a growth opportunity driven by infrastructure demand and AI-linked projects, but faces risks from premium valuation (P/E 39.2), weak cash flow trends, and communications segment softness. Investors should weigh strong institutional interest against execution challenges in a competitive market.
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
